Mantle cell lymphoma (MCL) is a malignancy of the non-Hodgkin’s type (NHL) and accounts for 3-10% of NHL. It frequently affects middle-aged to older males. It is thought to arise from peripheral B cells of the inner mantle zone and is associated with CCDN1 translocation. MCL presents late at stage III-IV. It is characterised by expression of B-cell markers CD19, CD20, CD22, CD79a and BSAP/PAX5.
MCL is aggressive and incurable with an average survival of 3-4 years. It is associated with rapid progression, temporary response to chemotherapy and high recurrence rate. There is no widely accepted first line therapy for MCL. Anthracyclines and CHOP regimen have been used with varying results. Although MCL is standardly CD20 positive, the anti-CD20 antibody rituximab has shown less of a positive effect in terms of response in comparison to other B-cell malignancies. Many other targeted drugs as well as vaccines are in the pipeline.
By choosing to continue, you are confirming that you are a healthcare professional